# Phase 1 Study of ANAVEX3-71

> **NCT04442945** · PHASE1 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ANAVEX3-71
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04442945
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-03
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442945, "Phase 1 Study of ANAVEX3-71". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04442945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*